Causes of Hypervitaminosis D
Hypervitaminosis D results from three primary mechanisms: excessive exogenous vitamin D intake (iatrogenic or accidental), endogenous overproduction of active vitamin D metabolites in granulomatous diseases and lymphomas, or genetic defects in vitamin D metabolism—with exogenous overdosing being the most common cause in clinical practice.
Exogenous (Iatrogenic) Causes
The most frequent cause of hypervitaminosis D is excessive intake of vitamin D supplements, which manifests when 25(OH)D levels exceed 150 ng/mL (375 nmol/L) 1, 2. This occurs through several mechanisms:
Intentional or Accidental Overdosing
- Dispensing errors: A documented case involved a patient prescribed 1000 IU daily but mistakenly given 50,000 IU daily, resulting in severe hypercalcemia and acute kidney injury within 3 months 3
- Contaminated food products: Eight patients developed hypervitaminosis D from milk incorrectly fortified with vitamin D3 at concentrations up to 232,565 IU per quart—far exceeding safe levels 4
- Self-administration: Increasing public awareness of vitamin D benefits has led to unsupervised intake of doses exceeding recommended limits 2
High-Dose Therapeutic Regimens
While the Endocrine Society guidelines recommend up to 10,000 IU daily for specific populations (obese patients, those on medications affecting vitamin D metabolism), these doses require monitoring to prevent toxicity 5. The upper safety limit is generally 4,000 IU daily for the general population 1.
Endogenous Overproduction
Granulomatous Disorders
Patients with chronic granuloma-forming conditions produce 1,25(OH)2D in an unregulated fashion through activated macrophages 5. This includes:
- Sarcoidosis
- Tuberculosis
- Chronic fungal infections
These patients develop hypercalciuria and hypercalcemia typically when 25(OH)D exceeds 30 ng/mL, requiring careful monitoring and often glucocorticoid therapy to suppress ectopic production 5, 6.
Lymphoproliferative Malignancies
Some lymphomas produce excessive 1,25(OH)2D through similar mechanisms, though the evidence for this as a primary cause of hypercalcemia remains incomplete 7, 6.
Genetic Causes
CYP24A1 Loss-of-Function Mutations
The most clinically significant genetic cause involves mutations in the CYP24A1 gene, which encodes 24-hydroxylase—the enzyme responsible for catabolizing both 25(OH)D and 1,25(OH)2D 7, 8. The pathogenic variant c.1186C>T (p.Arg396Trp) causes:
- Elevated 1,25(OH)2D levels (upper normal or frankly elevated)
- PTH-independent hypercalcemia
- Hypercalciuria with nephrolithiasis and nephrocalcinosis
- Persistent hypercalcemia despite low/undetectable PTH 8
Clinical pearl: Consider CYP24A1 mutations when PTH-independent hypercalcemia persists with 1,25(OH)2D in the upper normal range, especially with a family history 8.
Other Genetic Disorders
- Childhood idiopathic hypercalcemia type 1: Bi-allelic variants affecting vitamin D catabolism 7
- Williams-Beuren syndrome: Causes moderate infantile hypercalcemia in 15% of cases, typically resolving by age 4 5, 7, 2
- Jansen's metaphyseal chondrodysplasia: Activating PTH1R mutations causing hypercalcemia between 1 month and 10 years 7
Clinical Manifestations and Thresholds
Hypervitaminosis D traditionally manifests with hypercalcemia when 25(OH)D exceeds 150 ng/mL, producing 1, 2:
- Generalized symptoms: Fatigue, weakness, confusion, apathy
- Neurological: Altered mental status, irritability, potentially coma
- Gastrointestinal: Nausea, vomiting, constipation, abdominal pain
- Renal: Polyuria, polydipsia, dehydration, kidney stones, acute kidney injury
- Hematological effects: Negative correlation with hemoglobin, hematocrit, and RBC levels at very high concentrations 9
Critical Pitfalls to Avoid
Vitamin D "hypersensitivity": Some patients develop hypercalcemia even at doses considered safe for the general population, reflecting dysregulated metabolism 2. This requires individualized monitoring.
Duration of toxicity varies by preparation: Hypercalcemia from D2 or D3 persists for months due to fat storage, while toxicity from 1α(OH)D3 or 1,25(OH)2D3 resolves within a week 6.
Patients with extrarenal 1α-hydroxylase activity (granulomatous diseases) require serial monitoring of both 25(OH)D and calcium levels during any vitamin D treatment 5.
Infants and children: Overzealous supplementation in breastfed infants, particularly in settings with adequate sun exposure, can cause hypervitaminosis D 10. Children with Williams syndrome are particularly susceptible 5.